Results 31 to 40 of about 3,746,463 (320)

Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions. [PDF]

, 2020
ObjectiveTo evaluate whether biologic disease-modifying antirheumatic drugs (DMARDs) decrease cardiovascular disease (CVD) risk in rheumatoid arthritis (RA) and whether biologic DMARDs might have a beneficial effect on coronary plaque formation or ...
Budoff, Matthew J, Hernandez, Elizabeth, Karpouzas, George A, Ormseth, Sarah R   +3 more
core   +1 more source

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022

Научно-практическая ревматология, 2023
The article presents updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov   +7 more
doaj   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source

Tuberculosis in patients using biological disease-modifying antirheumatic drugs

Northwestern Medical Journal, 2023
Aim: In rheumatic diseases, the possibility of developing tuberculosis (TB) increases due to both the disease itself and the biological disease-modifying antirheumatic drugs (bDMARDs) used for treatment.
Emine Afşin, Furkan Küçük, Murat Taşçı   +2 more
doaj   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

Turkish Journal of Medical Sciences, 2020
In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome.
A. Tufan, Aslıhan Avanoğlu Güler, M. Matucci-Cerinic   +2 more
semanticscholar   +1 more source

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA

Научно-практическая ревматология, 2016
The paper gives the latest data on the impact of traditional cardiovascular risk factors, chronic inflammation, antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.
T. V. Popkova, D. S. Novikova, E. L. Nasonov   +2 more
doaj   +1 more source

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Annals of the Rheumatic Diseases, 2010
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and consensual international recommendations on RA treatment are not available.
J. Smolen, R. Landewé, F. Breedveld, M. Dougados, P. Emery, C. Gaujoux-Viala, S. Gorter, R. Knevel, J. Nam, M. Schoels, D. Aletaha, M. Buch, L. Gossec, T. Huizinga, J. Bijlsma, G. Burmester, B. Combe, M. Cutolo, C. Gabay, J. Gómez-Reino, M. Kouloumas, T. Kvien, E. Martı́n-Mola, I. McInnes, K. Pavelka, P. V. van Riel, Marieke Scholte, D. Scott, T. Sokka, G. Valesini, R. V. van Vollenhoven, K. Winthrop, J. Wong, A. Zink, D. M. van der Heijde   +34 more
semanticscholar   +1 more source

Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis

Arthritis care & research, 2020
We performed a systematic review and meta‐analysis to evaluate the comparative effects of tumor necrosis factor inhibitors (TNFi), non‐TNFi biologics, and conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) on cardiovascular risk in ...
Siddharth Singh, M. Fumery, A. Singh, Namrata Singh, L. Prokop, P. Dulai, W. Sandborn, J. Curtis   +7 more
semanticscholar   +1 more source